Influenza Nucleic Acid Molecules And Vaccines Made Therefrom

Patent metadata

Field	Value
Publication number	US-2016038584-A1
Application number	US-201414774256-A
Country	US
Kind code	A1
Filing date	Mar 12, 2014
Priority date	Mar 12, 2013
Publication date	Feb 11, 2016
Grant date	—

Abstract

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided.

First claim

1 . A multiple consensus subtype vaccine wherein the vaccine provides cross-reactivity against a variety of influenza strains, the vaccine comprising at least one consensus hemagglutinin antigen.

2 . The vaccine of claim 1 , wherein the consensus hemagglutinin antigen is selected from the group consisting of H1 hemagglutinin, H2 hemagluttinin, H3 hemagglutinin, and influenza B hemagglutinin, and any combination thereof.

3 . The vaccine of claim 2 , wherein the H1 hemagglutinin is selected from the group consisting of HS09, H1Bris, H1TT, H1U, and any combination thereof.

4 . The vaccine of claim 2 , wherein the H3 hemagglutinin is selected from the group consisting of H3HA-1, H3HA-2, and any combination thereof.

5 . The vaccine of claim 2 , wherein the influenza B hemagglutinin is selected from the group consisting of BHA-1, BHA-2, and any combination thereof.

6 . The vaccine of claim 3 , wherein HS09 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:2, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:2; a fragment of nucleic acid sequences encoding SEQ ID NO:2; a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:2;
wherein H1Bris comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:20, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:20; a fragment of nucleic acid sequences encoding SEQ ID NO:20; a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:20; wherein H1TT comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:22, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:22; a fragment of nucleic acid sequences encoding SEQ ID NO:22; a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:22; wherein H1U comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:36, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:36; a fragment of nucleic acid sequences encoding SEQ ID NO:36; a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:36.

7 . The vaccine of claim 3 , wherein HS09 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:1; a fragment of SEQ ID NO:1; a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:1;
wherein H1Bris comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:19, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:19; a fragment of SEQ ID NO:19; a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:19; wherein H1TT comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:21, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:21; a fragment of SEQ ID NO:21; a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:21; and wherein H1U comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:35, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:35; a fragment of SEQ ID NO:35; a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:35.

8 . The vaccine of claim 4 , wherein H3HA-1 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:38, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:38; a fragment of nucleic acid sequences encoding SEQ ID NO:38; a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:38;
wherein H3HA-2 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:24, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:24; a fragment of nucleic acid sequences encoding SEQ ID NO:24; a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:24.

9 . The vaccine of claim 4 , wherein H3HA-1 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:37, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:37; a fragment of SEQ ID NO:37; a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:37;
wherein H3HA-2 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:23, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:23; a fragment of SEQ ID NO:23; a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:23.

10 . The vaccine of claim 5 , wherein BHA-1 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:14, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:14; a fragment of nucleic acid sequences encoding SEQ ID NO:14; a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:14;
wherein BHA-2 comprises a nucleic acid sequence selected from the group consisting of a nucleic acid sequence encoding SEQ ID NO:26, a nucleic acid sequence that is at least 95% homologous to nucleic acid sequences encoding SEQ ID NO:26; a fragment of nucleic acid sequences encoding SEQ ID NO:26; a nucleic acid sequence that is at least 95% homologous to a fragment of nucleic acid sequences encoding SEQ ID NO:26.

11 . The vaccine of claim 5 , wherein BHA-1 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:13, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:13; a fragment of SEQ ID NO:13; a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:13;
wherein BHA-2 comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:25, a nucleic acid sequence that is at least 95% homologous to SEQ ID NO:25; a fragment of SEQ ID NO:25; a nucleic acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:25.

12 . A method of inducing cross-reactivity against a variety of influenza strains in a mammal, the method comprising administering to the mammal in need thereof the vaccine of claim 1 .

13 . The method of claim 12 , wherein each of the consensus hemagglutinin antigen is administered to the mammal separately.

14 . The method of claim 12 , wherein each of the consensus hemagglutinin antigen is administered to the mammal simultaneously.

15 . An isolated nucleic acid molecule comprising one or more nucleic acid sequences selected from the group consisting of:
a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:2, a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:20, a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:22, a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:36, a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:38, a nucleic acid sequence encoding the am

Assignees

• Weiner David
• Yan Jian
• Inovio Pharmaceuticals Inc
• Univ Pennsylvania

Inventors

• Weiner David B
• Yan Jian
• Morrow Matthew

Classifications

• A61P31/20

  for DNA viruses · CPC title

• A61P37/04

  Immunostimulants · CPC title

• C12N2710/20022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title